[go: up one dir, main page]

AR097038A1 - Uso de un ligando de cd6 y método basado en el - Google Patents

Uso de un ligando de cd6 y método basado en el

Info

Publication number
AR097038A1
AR097038A1 ARP140102744A ARP140102744A AR097038A1 AR 097038 A1 AR097038 A1 AR 097038A1 AR P140102744 A ARP140102744 A AR P140102744A AR P140102744 A ARP140102744 A AR P140102744A AR 097038 A1 AR097038 A1 AR 097038A1
Authority
AR
Argentina
Prior art keywords
methods
lymphocytes
auxiliary
cells
treatment
Prior art date
Application number
ARP140102744A
Other languages
English (en)
Inventor
Enrique Montero Casimiro Jose
Bughani Usha
Barve Abhijit
Nair Pradip
Melarkode Ramakrishnan
S Manian Bala
Original Assignee
Centro De Inmunología Molecular
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Inmunología Molecular, Biocon Ltd filed Critical Centro De Inmunología Molecular
Publication of AR097038A1 publication Critical patent/AR097038A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente trata sobre los métodos para el tratamiento y la prevención de condiciones mediadas por linfocitos T (células T), T-auxiliar 17 (Thl7) y/o T-auxiliar 1 (Th1). En particular, la presente trata sobre el uso de anticuerpos anti CD6 para el tratamiento de condiciones mediadas por linfocitos T autorreactivos Th17 y Th1. Los métodos de la presente tienen posterior utilidad en métodos para modular una respuesta inmune mediante la supresión de la producción de citoquina IL-23R, disminuyendo por lo tanto la inflamación mediada por las células Th17. Reivindicación 6: El compañero de unión que se une específicamente a CD6 para su uso según la reivindicación 4, en donde el anticuerpo humanizado es Itolizumab.
ARP140102744A 2013-07-23 2014-07-24 Uso de un ligando de cd6 y método basado en el AR097038A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3264CH2013 2013-07-23

Publications (1)

Publication Number Publication Date
AR097038A1 true AR097038A1 (es) 2016-02-17

Family

ID=52392806

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102744A AR097038A1 (es) 2013-07-23 2014-07-24 Uso de un ligando de cd6 y método basado en el

Country Status (15)

Country Link
US (3) US10189899B2 (es)
EP (3) EP3738613A1 (es)
JP (4) JP6530391B2 (es)
KR (3) KR102034757B1 (es)
AR (1) AR097038A1 (es)
AU (3) AU2014294616B2 (es)
CA (1) CA2920368C (es)
DK (1) DK3024485T3 (es)
ES (1) ES2843683T3 (es)
HK (1) HK1225298A1 (es)
NZ (1) NZ746944A (es)
PL (1) PL3024485T3 (es)
PT (1) PT3024485T (es)
TW (1) TW201511772A (es)
WO (1) WO2015011658A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0822447A2 (pt) 2008-03-14 2015-06-16 Biocon Ltd Anticorpo monoclonal e método do mesmo
EP3738613A1 (en) 2013-07-23 2020-11-18 Biocon Limited Use of a cd6 binding partner and method based thereon
CA3076861A1 (en) * 2016-10-18 2018-04-26 Biocon Limited Use of itolizumab to reduce phosphorylation of cd6
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
US12281151B2 (en) 2018-06-29 2025-04-22 City Of Hope CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
WO2022067240A1 (en) * 2020-09-28 2022-03-31 Vor Biopharma, Inc. Compositions and methods for cd6 modification
WO2022120240A1 (en) * 2020-12-04 2022-06-09 Equillium, Inc. Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
EP0726912A4 (en) 1993-11-02 2000-08-23 Univ Duke Cd6 ligand
US5998172A (en) 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
EP0888292B1 (fr) 1996-03-20 2001-10-31 Aventis Pharma S.A. COMPOSES TRICYCLIQUES AYANT UNE ACTIVITE VIS-A-VIS DES INTEGRINES NOTAMMENT VIS-A-VIS DE L'INTEGRINE ALPHA vBETA3, LEUR PROCEDE DE PREPARATION ET LES INTERMEDIAIRES DE CE PROCEDE, LEUR APPLICATION A TITRE DE MEDICAMENTS ET LES COMPOSITIONS PHARMACEUTIQUES LES RENFERMANT
EP0977991A4 (en) * 1997-03-03 2004-12-15 Bristol Myers Squibb Co MONOCLONAL ANTIBODIES FOR HUMAN CD6
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
WO2000058362A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
ES2254174T3 (es) 1999-05-07 2006-06-16 Genentech, Inc. Tratamiento de enfermedades autoinmunes con antagonistas que se unen a marcadores de superficie de linfocitos b.
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
JP2003527861A (ja) 2000-03-16 2003-09-24 ジェネンテック・インコーポレーテッド 増強した抗血液凝固能を持つ抗組織因子抗体
AU2001266604A1 (en) 2000-05-26 2001-12-11 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
ES2192128B1 (es) 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2003265361A1 (en) 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
CA2519408C (en) 2003-04-04 2011-01-18 Genentech, Inc. High concentration antibody and protein formulations
US20060122377A1 (en) 2004-02-19 2006-06-08 Genentech, Inc. CDR-repaired antibodies
SG10201606980VA (en) * 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
EP2325206B1 (en) 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
RU2007124933A (ru) 2005-01-28 2009-03-10 Вайет (Us) Стабилизированные жидкие полипептидные составы
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
EA200870538A1 (ru) 2006-06-14 2009-04-28 Имклоун Системз Инкорпорейтед Лиофилизированные композиции анти-egfr антител
AU2007331712A1 (en) 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
CN101199483B (zh) 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
PL2119452T3 (pl) 2006-12-26 2021-03-08 Centro De Inmunologia Molecular Kompozycja farmaceutyczna zawierająca przeciwciało monoklonalne anty-cd6 do zastosowania w diagnostyce i leczeniu reumatoidalnego zapalenia stawów
CN101678101B (zh) 2006-12-26 2012-11-07 分子免疫中心 可用于诊断和治疗b细胞慢性淋巴细胞白血病的能够在肿瘤细胞中诱导凋亡的药物组合物
CL2008000058A1 (es) 2007-01-09 2008-05-23 Wyeth Corp Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
JP2010111581A (ja) * 2007-01-25 2010-05-20 Imuno:Kk ドーパミンｄ２様受容体アゴニストを有効成分とする医薬及びスクリーニング方法
EP2057194B1 (en) * 2007-02-28 2013-03-20 Merck Sharp & Dohme Corp. Engineered anti-il-23r antibodies
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
MX2009013886A (es) 2007-06-25 2010-01-27 Amgen Inc Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos.
WO2009037190A2 (en) 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
WO2009092087A2 (en) * 2008-01-18 2009-07-23 The Brigham And Women's Hospital, Inc. Selective differentiation, identification, and modulation of human th17 cells
BRPI0822447A2 (pt) * 2008-03-14 2015-06-16 Biocon Ltd Anticorpo monoclonal e método do mesmo
BR112012012080B1 (pt) 2009-11-20 2022-11-29 Biocon Limited Formulações de histidina-trealose do anticorpo t1h
GB201013975D0 (en) * 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
US9216988B2 (en) * 2011-12-22 2015-12-22 Genentech, Inc. Benzyl sulfonamide derivatives as RORc modulators
CN102559636B (zh) 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
EP3738613A1 (en) 2013-07-23 2020-11-18 Biocon Limited Use of a cd6 binding partner and method based thereon
CA3076861A1 (en) 2016-10-18 2018-04-26 Biocon Limited Use of itolizumab to reduce phosphorylation of cd6
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
JP7572041B2 (ja) 2018-02-27 2024-10-23 エクイリウム，インコーポレイテッド 重症喘息を処置するための組成物および方法

Also Published As

Publication number Publication date
EP3024485B1 (en) 2020-11-18
CA2920368A1 (en) 2015-01-29
AU2021240292A1 (en) 2021-10-28
US20190345247A1 (en) 2019-11-14
JP2022145689A (ja) 2022-10-04
US20160152705A1 (en) 2016-06-02
CA2920368C (en) 2023-03-21
JP7221264B2 (ja) 2023-02-13
KR102405247B1 (ko) 2022-06-07
KR102276745B1 (ko) 2021-07-14
PT3024485T (pt) 2021-01-25
DK3024485T3 (da) 2020-12-07
AU2014294616A1 (en) 2016-02-18
EP3738613A1 (en) 2020-11-18
NZ716381A (en) 2021-06-25
KR20190120426A (ko) 2019-10-23
PL3024485T3 (pl) 2021-06-14
EP3936148A1 (en) 2022-01-12
JP2019112446A (ja) 2019-07-11
AU2019246781A1 (en) 2019-10-31
US11028168B2 (en) 2021-06-08
EP3024485A1 (en) 2016-06-01
AU2014294616B2 (en) 2019-07-11
AU2019246781B2 (en) 2021-07-01
US10189899B2 (en) 2019-01-29
JP6868655B2 (ja) 2021-05-12
KR20160033786A (ko) 2016-03-28
AU2021240292B2 (en) 2025-01-23
JP2016525538A (ja) 2016-08-25
KR102034757B1 (ko) 2019-10-21
NZ746944A (en) 2021-07-30
JP2021038266A (ja) 2021-03-11
EP3024485A4 (en) 2017-03-08
ES2843683T3 (es) 2021-07-20
WO2015011658A1 (en) 2015-01-29
KR20210088739A (ko) 2021-07-14
TW201511772A (zh) 2015-04-01
HK1225298A1 (zh) 2017-09-08
JP6530391B2 (ja) 2019-06-12
US20220025038A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
AR097038A1 (es) Uso de un ligando de cd6 y método basado en el
ECSP18043564A (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
MX2020006213A (es) Anticuerpos anti-trem2 y metodos relacionados.
MX2024001803A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
AR114283A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CL2018001177A1 (es) Anticuerpos vinculados especificamente a pd-1 y sus usos.
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
AR108800A1 (es) Purificación de anticuerpos multiespecíficos
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
CO7400878A2 (es) Anticuerpos anti-mcam y métodos de uso asociados
MX383464B (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2015007034A (es) Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
AR090585A1 (es) Anticuerpos anti-hla-b*27 y usos de estos
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения

Legal Events

Date Code Title Description
FB Suspension of granting procedure